Flyer
Proteomics Services
- Our Services
- Platforms
- Target Solutions
- Technologies
- Service Types
- Our Science
- About Us
- Contact us
Our state-of-the-art proteomics platform supports a diverse range of applications, including:
Large-scale, unbiased protein quantification for biomarker discovery and systems biology.
Reveal regulatory protein modifications that drive signaling, immune response, and disease progression.
Precision quantification of selected proteins or peptides—ideal for validation and clinical research.
Our proteomics services are instrumental in addressing key questions across various research areas:
Comprehensive protein expression analysis of cells, tissues, and biofluids, with capabilities for comparative studies across different treatment conditions, disease states, or genetic backgrounds.
In-depth investigation of protein dysregulation in various pathologies, contributing to a better understanding of disease etiology and progression.
Identification and validation of protein-based biomarkers for disease diagnosis, prognosis, and therapeutic response prediction, enabling precision medicine approaches.
Discovery and functional validation of novel therapeutic targets, facilitating the development of innovative therapeutic strategies.
Elucidation of drug targets, off-target effects, and pathway modulation, providing mechanistic insights into drug efficacy and potential adverse events.
Integration and correlation with genomics, transcriptomics, and metabolomics data to provide a holistic view of biological systems, supported by customized bioinformatics pipelines.
Crown Bioscience leverages next-generation mass spectrometry platforms to overcome traditional proteomic challenges, offering distinct advantages:
The DIA (Data-Independent Acquisition) strategy, particularly diaPASEF, minimizes missing values and batch effects, ensuring highly reproducible quantification across large datasets. This enhances data parallelism and traceability.
Our platforms identify and quantify significantly more proteins, including low-abundance proteins, from smaller sample inputs. This is crucial for comprehensive proteome coverage and detecting subtle biological changes.
Optimized workflows allow for robust proteomic analysis with lower sample quantities, making our services suitable for precious clinical samples and challenging biological matrices.
Our robust and automated sample preparation combined with high-speed data acquisition allows for the efficient processing of thousands of samples, crucial for statistically powered biomarker discovery and validation studies.
Dedicated bioinformatics experts provide tailored data processing, statistical analysis, and biological interpretation, transforming raw data into actionable insights relevant to your research objectives.
Proteins are the primary executors of biological functions, and their activity levels often directly manifest disease states. While genomics provides information on gene potential, it cannot fully reflect the dynamic complexity of protein expression, localization, post-transcriptional modifications, and interactions, all of which profoundly impact cellular processes and disease pathogenesis. Mass spectrometry-based proteomics directly addresses this gap by enabling direct quantification and characterization of proteins, offering a more direct correlation to phenotypic changes. Given the inherent complexity and wide dynamic range of the proteome, advanced MS technologies are essential for achieving comprehensive coverage and accurate quantification.
The landscape of small molecule drug discovery has been revolutionized by the advent of induced targeted protein degradation, exemplified by PROteolysis TArgeting Chimeras (PROTACs) and the emerging class of molecular glues. These innovative modalities harness the cell's inherent ubiquitin-proteasome system (UPS) to selectively degrade pathological proteins, offering a novel therapeutic strategy. The intricate mechanisms governing PROTAC and molecular glue action necessitate the comprehensive application of advanced proteomics throughout their entire drug development lifecycle. This includes critical stages such as target identification and validation, lead compound optimization, mechanistic elucidation, and detailed preclinical characterization, providing essential insights for successful protein degrader development and targeted protein degradation strategies.
Our mass spectrometry-based proteomics services are uniquely positioned to support Targeted Protein Degradation research by providing crucial insights into:
Our dedicated proteomics facility is equipped with a comprehensive suite of high-performance mass spectrometers and complementary technologies, ensuring leading-edge capabilities:
Our arsenal includes over 20 top-tier mass spectrometers, notably the Bruker timsTOF Pro and timsTOF Pro 2 series, and the Thermo Fisher Scientific Orbitrap Exploris™ 480. These instruments offer exceptional mass accuracy, resolution, and sensitivity.
We integrate additional separation dimensions through ion mobility spectrometry, including Bruker Trapped Ion Mobility Spectrometry (TIMS) and Thermo Fisher Scientific FAIMS technology. This orthogonal separation provides enhanced signal-to-noise, reduces sample complexity, and improves the confidence of peptide and protein identification and quantification.
Leveraging the proprietary diaPASEF (Data-Independent Acquisition Parallel Accumulation Serial Fragmentation) on timsTOF platforms, we achieve dramatically increased data acquisition speed and sensitivity without compromising coverage or quantitative accuracy.
Our workflows incorporate the Evosep One system, providing highly robust and reproducible ultra-low flow chromatographic separation, critical for maximizing peptide identification and quantification in large-scale studies.
Our systems are optimized for continuous analysis of thousands of samples, ensuring stable performance and reduced instrument downtime, which significantly enhances the reliability of batch analyses.
Crown Bioscience provides comprehensive bioinformatics support, transforming complex raw data into meaningful biological insights:
Tailored analytical pipelines for identifying and prioritizing proteomic biomarkers in preclinical models.
Sophisticated statistical and pathway analysis, protein-protein interaction mapping, and functional annotation to interpret proteomic datasets.
Capabilities for integrating proteomic data with genomics, transcriptomics, and other omics datasets, providing a systems-level understanding of biological processes.
Mouse Stromal Cells Confound Proteomic Characterization and Quantification of Xenograft Models
Systematic Evaluation of Label-Free Protein Quantification Pipelines (DDA vs DIA)
